4basebio UK Societas (88Q) Price & Analysis

0 Followers

88Q Stock Chart & Stats

€7.95

€0.10(0.69%)

At close: Jan 09 4:00 PM EST

€7.95

€0.10(0.69%)

Day’s Range― - ―

52-Week Range€4.64 - €9.50

Previous CloseN/A

Volume140.00

Average Volume (3M)218.00

Market Cap

€101.97M

Enterprise Value€89.85

Total Cash (Recent Filing)€14.05M

Total Debt (Recent Filing)€23.10M

Price to Earnings (P/E)―

Beta0.25

Next Earnings

Jun 02, 2027

EPS Estimate

-0.7

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.16

Shares Outstanding15,538,518

10 Day Avg. Volume338

30 Day Avg. Volume218

Financial Highlights & Ratios

PEG Ratio-0.35

Price to Book (P/B)9.43

Price to Sales (P/S)56.33

P/FCF Ratio-6.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€11.65

Price Target Upside46.60% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.01

Revenue Forecast (FY)€30.23K

Bulls Say, Bears Say

Bulls Say

Synthetic DNA PositioningThe company is positioned in a specialized enabling segment of biotechnology, supplying synthetic DNA and related capabilities for gene therapies, vaccines, and genetic medicines. This focus gives the business a clear role in supporting biopharma development and manufacturing workflows over the medium term.

Long-term Revenue ExpansionDespite a decline in 2025, the company has expanded revenue over the 2020–2025 period and reports an 81.46% revenue-growth metric. Growth from a small base indicates that its products and capabilities have achieved some commercial scaling, supporting future operating leverage if expansion resumes.

Positive Gross MarginPositive gross margin indicates that 4basebio captures value above direct production costs, providing an underlying economic contribution from its offerings. Although volatility and high operating costs currently prevent profitability, this gross-profit base could support improved earnings if revenue scales or expenses become more efficient.

Bears Say

Persistent And Widening LossesThe combination of declining 2025 revenue and materially wider losses shows that the business has not yet converted its technology and revenue base into sustainable profitability. Negative operating and net margins leave limited internal funding capacity and make earnings improvement dependent on renewed growth or cost control.

Accelerating Cash BurnPersistent negative operating and free cash flow means the company is consuming cash rather than self-funding operations. The acceleration in 2025 increases the importance of revenue scaling, expense reductions, or external financing, and can constrain investment in product development and manufacturing capabilities.

Deteriorating Balance SheetHigher debt alongside sharply lower equity weakens financial flexibility and increases the burden placed on a loss-making business. Declining assets and elevated debt-to-equity can restrict capital-allocation options, while continued losses could increase dilution or funding pressure if external capital is required.

4basebio UK Societas News

4basebio Pipeline Surges as Synthetic DNA Demand Builds Despite Lower First-Half Revenue

4basebio UK Societas ( ($GB:4BB) ) has issued an announcement. 4basebio reported strong commercial momentum in the first...

4d ago

4basebio and TriLink Forge Cell Therapy Supply Pact With Tier 1 Pharma

The latest announcement is out from 4basebio UK Societas ( ($GB:4BB) ). 4basebio has agreed to supply its...

4d ago

4basebio Boosts Synthetic DNA Capacity for Personalised mRNA Medicines

An announcement from 4basebio UK Societas ( ($GB:4BB) ) is now available. 4basebio PLC has expanded its high...

25d ago

4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing

4basebio UK Societas ( ($GB:4BB) ) has issued an update. 4basebio PLC, a UK-listed biotech focused on synthetic,...

1M ago

4basebio awards new management share options to support long-term growth

The latest update is out from 4basebio UK Societas ( ($GB:4BB) ). 4basebio PLC has granted a total...

2M ago

4basebio strengthens board with deep tech investor Cornel Chiriac

4basebio UK Societas ( ($GB:4BB) ) has provided an update. 4basebio PLC has appointed Mr. Cornel Chiriac as...

3M ago

4basebio Secures AGM Backing and Awards New Employee Share Options

The latest announcement is out from 4basebio UK Societas ( ($GB:4BB) ). 4basebio PLC reported that all resolutions...

3M ago

4basebio Sets Investor Presentation as It Advances Synthetic DNA Platform

The latest announcement is out from 4basebio UK Societas ( ($GB:4BB) ). 4basebio PLC, a Cambridge-based biotechnology company...

4M ago

4basebio CEO Increases Stake with Market Purchase of Ordinary Shares

4basebio UK Societas ( ($GB:4BB) ) just unveiled an announcement. 4basebio PLC, a Cambridge-based biotechnology company specialising in...

4M ago

4basebio ramps up commercial push as revenue surges and GMP wins fuel synthetic DNA growth

4basebio UK Societas ( ($GB:4BB) ) has shared an announcement. 4basebio reported an 81% increase in revenue to...

4M ago

88Q FAQ

What was 4basebio UK Societas’s price range in the past 12 months?

4basebio UK Societas lowest stock price was €4.64 and its highest was €9.50 in the past 12 months.

What is 4basebio UK Societas’s market cap?

4basebio UK Societas’s market cap is €101.97M.

When is 4basebio UK Societas’s upcoming earnings report date?

4basebio UK Societas’s upcoming earnings report date is Jun 02, 2027 which is in 244 days.

How were 4basebio UK Societas’s earnings last quarter?

4basebio UK Societas released its earnings results on Sep 25, 2026. The company reported -€0.674 earnings per share for the quarter.

Is 4basebio UK Societas overvalued?

According to Wall Street analysts 4basebio UK Societas’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does 4basebio UK Societas pay dividends?

4basebio UK Societas does not currently pay dividends.

What is 4basebio UK Societas’s EPS estimate?

4basebio UK Societas’s EPS estimate is -0.7.

How many shares outstanding does 4basebio UK Societas have?

4basebio UK Societas has 15,538,518 shares outstanding.

What happened to 4basebio UK Societas’s price movement after its last earnings report?

4basebio UK Societas reported an EPS of -€0.674 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of 4basebio UK Societas?

Currently, no hedge funds are holding shares in DE:88Q

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

4basebio UK Societas Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-26.46%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

4basebio UK Societas

4basebio PLC, an enterprise established in 2020 and situated in Cambridge, United Kingdom, is dedicated to the entire process, from conception to delivery, of synthetic DNA and RNA products. The company also provides advanced non-viral vector solutions, with operations spanning the United States, Europe, and other international markets. Their comprehensive offerings encompass research kits, bulk enzymes, various other biological products, as well as crucial licensing and AVV manufacturing services. The company primarily caters to clients within the biotech, pharmaceutical, and contract development and manufacturing organization (CDMO) industries. Notably, the firm adopted its current name, 4basebio PLC, in July 2021, having previously been known as 4basebio UK Societas.

4basebio UK Societas (88Q) Earnings & Revenues

Historic Earnings Reports

88Q Stock 12 Month Forecast

Average Price Target

€11.65

▲(46.60% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","6":"€6","8":"€8","10":"€10","12":"€12"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11.65489,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€11.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.65489,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€11.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.65489,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€11.65</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,6,8,10,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.85,6.29653,6.74306,7.18959,7.63612,8.08265,8.52918,8.97571,9.42224,9.86877,10.3153,10.76183,11.208359999999999,{"y":11.65489,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.85,6.29653,6.74306,7.18959,7.63612,8.08265,8.52918,8.97571,9.42224,9.86877,10.3153,10.76183,11.208359999999999,{"y":11.65489,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.85,6.29653,6.74306,7.18959,7.63612,8.08265,8.52918,8.97571,9.42224,9.86877,10.3153,10.76183,11.208359999999999,{"y":11.65489,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.85,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.65,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.65,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.9,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >